Unlike the general population, patients on maintenance hemodialysis have both traditional and nontraditional risk factors that put them at high cardiovascular risk, despite use of standard lipid and ...
Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback